Collaborations and Licensing Agreements - Additional Information (Details)			3 Months Ended		6 Months Ended
	Aug. 07, 2021 USD ($) $ / shares shares	Jan. 01, 2011 Optiontarget	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jul. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Regulatory milestone payments obligation									$ 900,000
Reimbursements receivable of regulatory milestone									$ 1,000,000.0
Roche [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Regulatory milestone payments obligation										$ 1,000,000.0
Notice period in days					90 days
Research and Development Obligation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Estimated variable consideration					$ 4,000,000.0
Manufacturing Material [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue			$ 3,800,000
License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Transaction Price			11,800,000
License Revenue [Member] | License, Research and Development Service [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Transaction Price					4,700,000
Transaction price recognized			800
License and Material Right [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Transaction Price			600,000
Transaction price recognized			100,000
HutchMed License Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Percentage cost incurred for global studies and total number of patients enrolled In the territory	20.00%
Percentage cost incurred for global studies not specific to any territory	20.00%
Development and regulatory milestone payment	$ 110,000,000.0
Royalties payable for licensed product, description	Royalties are payable for each Licensed Product commencing on the first commercial sale of the applicable Licensed Product and ending, on a Jurisdiction-by-Jurisdiction basis, on the latest of expiration of specified patent coverage, expiration of specified regulatory exclusivity or a specified period following the first commercial sale in such Jurisdiction and may be reduced in various circumstances.
Clinical license agreement expiration terms	HutchMed License Agreement will expire upon the expiration of the last royalty term for the last Licensed Product in the Field in the Territory. HutchMed may terminate the HutchMed License Agreement in its entirety for any or no reason upon 12 months’ prior written notice to the Company.
Upfront milestone					13,000,000.0
Nonrefundable upfront payment received	$ 25,000,000.0
HutchMed License Agreement [Member] | License, Research and Development Service [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Transaction Price					17,100,000
HutchMed License Agreement [Member] | License Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Total revenue					12,000,000.0
HutchMed License Agreement [Member] | License and Material Right [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue remaining performance obligation			12,000,000.0		12,000,000.0
HutchMed License Agreement [Member] | Common Stock [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Date prior to which warrants are exercisable	Aug. 07, 2025
Number of securities into which the class of warrant or right may be converted | shares	5,653,000
Exercise price of warrants | $ / shares	$ 11.50
HutchMed License Agreement [Member] | Maximum [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales milestone payment	$ 175,000,000.0
GSK [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Number of option targets | Optiontarget		3
Eisai [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Obligation related to World Wide Royalty			1,300,000	$ 1,200,000	2,600,000	$ 2,100,000
Other Receivables			100,000		100,000		$ 100,000
Royalties payable					1,300,000	1,200,000
Eisai [Member] | Tazemetostat Drug Pruducts [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenue								$ 5,000,000.0
Total revenue				$ 5,000,000.0		$ 6,300,000
Royalty Pharma and Pharmakon Advisors [Member] | Roche [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Remaining unpaid milestone payments			1,000,000.0		1,000,000.0						$ 10,400,000
Reimbursements receivable of development costs			$ 900,000		$ 900,000
Signed Amendment [Member] | Roche [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Regulatory milestone payments obligation										500,000
Fourth Amendment [Member] | Roche [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Regulatory milestone payments obligation										$ 500,000